Skip to main content

ADVERTISEMENT

saphenous vein grafts

Original Contribution
07/10/2023

Adnan Kassier, MD; Ronak Soni, MD; Kameel Kassab, MD; Dilpat Kumar, MBBS;Yashwant Agrawal, MD; Veera Pavan Kotaru, MD; Frank Saltiel, MD; Vishal Gupta, MD;  Jagadeesh Kalavakunta, MD; Tim A. Fischell, MD

Adnan Kassier, MD; Ronak Soni, MD; Ka...
Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVG) can be challenging due to no reflow phenomenon from distal embolization of debris and microvascular vasoconstriction, resulting in myocardial injury post-procedure....
Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVG) can be challenging due to no reflow phenomenon from distal embolization of debris and microvascular vasoconstriction, resulting in myocardial injury post-procedure....
Percutaneous coronary...
07/10/2023
Journal of Invasive Cardiology
Original Contribution
10/01/2015

Anna P. Kotsia, MD1;  Bavana V. Rangan, BDS, MPH1;  Georgios Christopoulos, MD1;  Ameka Coleman, BS1;  Michele Roesle, RN, BSN1;  Daisha Cipher, PhD2;  James A. de Lemos, MD1;  Darren K. McGuire, MD, MHSc1;  Milton Packer, MD1;  Subhash Banerjee, MD1;  Emmanouil S. Brilakis, MD, PhD1

Anna P. Kotsia, MD1;  Bavana V. Ranga...
Intermediate SVG lesions have high rates of progression. The purpose of this study was to examine the impact of extended-release niacin (ER-niacin) vs. placebo on intermediate saphenous vein graft (SVG) lesions.
Intermediate SVG lesions have high rates of progression. The purpose of this study was to examine the impact of extended-release niacin (ER-niacin) vs. placebo on intermediate saphenous vein graft (SVG) lesions.
Intermediate SVG lesions have...
10/01/2015
Journal of Invasive Cardiology